Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KMD111
- Development stage
- Preclinical
- Lead developer
- KMD Bio
- Modality
- Recombinant Proteins and Enzymes, Peptides, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
KMD111 is a novel HER2-targeted drug delivery platform developed by KMD Bio. It utilizes Protein Corona Shield Nanoparticle (PCSN) / Antibody Conjugated NanoParticles (ACNP) technology, consisting of mesoporous silica nanoparticles (MSNs) loaded with the topoisomerase I inhibitor SN-38 (the active metabolite of irinotecan) as a cytotoxic payload. The nanoparticles are coated with HER2-targeting affibody proteins via a glutathione-sensitive GST-GSH bio-linker. This design provides stability in the bloodstream and enables selective, glutathione-regulated drug release within the tumor microenvironment. KMD111 is being developed for the treatment of HER2-expressing solid tumors, including gastric and breast cancers.
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on KMD111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KMD111.